P-017: MagnetisMM-7: an open label, randomized, phase 3 study of elranatamab versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after transplant

Subjects

Subjects :

Cancer Research
Oncology
Hematology

Details

ISSN :

21522650

Volume :

22

Database :

OpenAIRE

Journal :

Clinical Lymphoma Myeloma and Leukemia

Accession number :

edsair.doi...........a356d9599d1cfcfa78fd62c3d380d7d5